Dr. Reddy's Laboratories Limited

Dr. Reddy’s Laboratories Ltd. announced the allotment of 375 equity shares of Re. 1/- each to eligible employees on September 10, 2026, following the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007, resulting in a total issued share capital of Rs. 83,46,81,285 /- and 83,46,80,285 equity shares.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 4,110 equity shares of Re. 1/- each to eligible employees on August 26, 2026, pursuant to the exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002, resulting in a total issued share capital of Rs. 83,46,80,910 /- and a total issued shares of 83,46,80,910.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced that the U.S. Food and Drug Administration has approved its rituximab biosimilar, developed and manufactured by Dr. Reddy’s Laboratories, for the U.S. market, with Fresenius Kabi holding the exclusive rights to commercialize the product in the United States. The approval follows a recent Pre-License Inspection at the company's biologics manufacturing facility in Bachupally, Hyderabad, and strengthens Dr. Reddy’s global biosimilars portfolio.

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.Powered by Capital Market - Live

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad, said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip slipped 1.95% to settle at Rs 1,183 on the BSE. Powered by Capital Market - Live

Net profit of Dr Reddy's Laboratories declined 68.67% to Rs 444.30 crore in the quarter ended June 2026 as against Rs 1418.10 crore during the previous quarter ended June 2025. Sales declined 5.56% to Rs 8070.50 crore in the quarter ended June 2026 as against Rs 8545.20 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales8070.508545.20 -6 OPM %10.6525.44 - PBDT1089.902381.10 -54 PBT553.301905.00 -71 NP444.301418.10 -69 Powered by Capital Market - Live

The board of Dr Reddys Laboratories at its meeting held on 22 July 2026 has appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel of the Company effective 22 July 2026.

Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1245.1, down 1.92% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.88% on the day, quoting at 24172.55. The Sensex is at 77454.26, up 0.93%.Dr Reddys Laboratories Ltd has lost around 2.42% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 5.38% in last one month and is currently quoting at 25656.25, down 0.16% on the day. The volume in the stock stood at 58.42 lakh shares today, compared to the daily average of 21.64 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1250.1, down 0.15% on the day. Dr Reddys Laboratories Ltd tumbled 0.77% in last one year as compared to a 3.89% slide in NIFTY and a 15.25% spurt in the Nifty Pharma index.The PE of the stock is 34.61 based on TTM earnings ending March 26.Powered by Capital Market - Live

JSW Dulux Ltd, Paras Defence and Space Technologies Ltd, Shaily Engineering Plastics Ltd and Solar Industries India Ltd are among the other losers in the BSE's 'A' group today, 09 July 2026.Dr Reddys Laboratories Ltd tumbled 5.99% to Rs 1267.95 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 3 lakh shares were traded on the counter so far as against the average daily volumes of 87319 shares in the past one month.JSW Dulux Ltd crashed 3.26% to Rs 2945.9. The stock was the second biggest loser in 'A' group.On the BSE, 1.03 lakh shares were traded on the counter so far as against the average daily volumes of 1610 shares in the past one month.Paras Defence and Space Technologies Ltd lost 3.20% to Rs 1232.9. The stock was the third biggest loser in 'A' group.On the BSE, 94727 shares were traded on the counter so far as against the average daily volumes of 4.39 lakh shares in the past one month.Shaily Engineering Plastics Ltd shed 3.10% to Rs 2706.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 18575 shares were traded on the counter so far as against the average daily volumes of 45235 shares in the past one month.Solar Industries India Ltd plummeted 3.04% to Rs 17412.65. The stock was the fifth biggest loser in 'A' group.On the BSE, 29723 shares were traded on the counter so far as against the average daily volumes of 9074 shares in the past one month.Powered by Capital Market - Live

The domestic benchmarks indices continued to trade with major gains in early afternoon trade supported by foreign fund inflows and buying in blue-chip stocks. The Nifty traded above the 24,050 mark. Investors are also closely tracking the first-quarter earnings season, with the focus on TCS' Q1 FY27 results due later in the day. Market participants will watch the IT major's management commentary for cues on discretionary technology spending by global clients and the demand outlook for the sector. Consumer durables shares rebounded after declining in the past trading session. At 12:25 IST, the barometer index, the S&P BSE Sensex declined 585.92 points o 0.76% to 77,091.46. The Nifty 50 index fell 183.45 points or 0.77% to 24,067.55. The broader market outperformed the frontline indices. The BSE 150 MidCap Index rose 1.48% and the BSE 250 SmallCap Index jumped 1.64%. The market breadth was strong. On the BSE, 2,878 shares rose and 1,086 shares fell. A total of 231 shares were unchanged. In the commodities market, Brent crude for September 2026 settlement fell 30 cents or 0.38% to $77.72 a barrel. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, tumbled 10.43% to 13.15. The Nifty 28 July 2026 futures were trading at 24,103 at a premium of 35.45 points as compared with the spot at 24,067.55. The Nifty option chain for the 28 July 2026 expiry showed a maximum call OI of 57.3 lakh contracts at the 25,000 strike price. A maximum put OI of 64.1 lakh contracts was seen at the 24,000 strike price. Buzzing Index: The Nifty Consumer Durables index jumped 2.01% to 37,957.50. The index declined 1.33% in the past trading session. Kalyan Jewellers India (up 16.48%), Dixon Technologies (India) (up 4.99%), PG Electroplast (up 2.97%), Amber Enterprises India (up 2.44%), Kajaria Ceramics (up 2.07%) were the top gainers. Among the other gainers were Blue Star (up 1.99%), Whirlpool of India (up 1.24%), Bata India (up 1.02%), LG Electronics India (up 0.9%) and Crompton Greaves Consumer Electricals (up 0.89%) surged. Stocks in Spotlight: Dr Reddy's Laboratories tumbled 5.24% after the company said commercial supplies of certain batches of its semaglutide product will be delayed following a quality-related issue involving the active pharmaceutical ingredient (API). The Phoenix Mills added 3.96% after the company reported a strong operational performance across its retail, commercial office, hospitality and residential businesses for the quarter ended June 2026 (Q1 FY27). The company's retail portfolio continued to deliver robust growth, with consumption rising 32% year-on-year (YoY) to Rs 4,727 crore during the quarter across its existing operational assets.Powered by Capital Market - Live